Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
Deptula-Hicks Brings More Than 25 Years of Financial Leadership Experience
LEXINGTON, Mass., April 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc.
(OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic
drugs and novel oncology therapeutics, today announced the appointment of
Darlene Deptula-Hicks to its Board of Directors.
Scott Maguire, CEO of Xenetic Biosciences said: "We are pleased to welcome
Darlene to the Board of Xenetic. Her extensive financial and business
experience, including public company CFO and board membership roles, will be
invaluable as we continue to grow Xenetic and further establish ourselves as a
US-based biopharmaceutical company."
"I am honored to join the Xenetic Board of Directors, particularly at this
pivotal stage in the Company's development," said Ms. Deptula-Hicks. "With its
diverse product pipeline and strong strategic collaborations, Xenetic is
well-positioned to create shareholder value and I look forward to contributing
to the Company's strategic growth."
Ms. Deptula-Hicks brings extensive financial leadership experience to the
Xenetic Board of Directors. She currently serves as the Vice President and
Chief Financial Officer of Microline Surgical, Inc., a leading global
manufacturer of reposable surgical laproscopic devices. Ms. Deptula-Hicks also
served as the Executive Vice President, Chief Financial Officer, Treasurer and
Secretary of ICAD, Inc., (Nasdaq:ICAD) a publicly traded medical device
company providing products and solutions for the early detection of cancer.
Previous to iCAD, Inc. Ms. Deptula-Hicks served as the Executive Vice
President, Chief Financial Officer and Treasurer of ONI Medical Systems, Inc.,
a designer and manufacturer of high-field diagnostic imaging systems for
orthopedic applications. Ms. Deptula-Hicks was the Executive Vice President
and Chief Financial Officer of Implant Sciences Corporation an early stage
medical device company that had its initial public offering in June of 1999.
Ms. Deptula-Hicks led the pre-IPO and post-IPO activities for the company. Ms.
Deptula-Hicks has also held similar roles, including at Abiomed, Inc., and GCA
Corporation. In addition, she has served on a number of Board of Directors and
Audit Committees, including the boards of NASDAQ-listed companies Technest
Holdings and IMCOR Pharmaceuticals and private company USFalcon. Ms.
Deptula-Hicks holds a B.A. from Southern New Hampshire University and an
M.B.A. from Rivier College. She also completed the executive education program
at Dartmouth's Tuck School of Business.
About Xenetic Biosciences
Xenetic Biosciences is a biopharmaceutical company developing next-generation
biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug
technology platforms include PolyXen® for creating next generation biologic
drugs by extending the efficacy, safety and half-life of biologic drugs and
OncoHist® for the development of novel oncology drugs focused on orphan
indications. Xenetic's lead product candidates include ErepoXen®, an improved,
polysialylated form of erythropoietin (EPO) for the treatment of anemia in
pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant
human histone H1.3 molecule which Xenetic is developing for the treatment of
refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series
of polysialylated blood coagulation factors through its license agreement with
Baxter International Inc. Xenetic is also developing a broad pipeline of
clinical candidates for next generation biologics and novel oncology
therapeutics in a number of orphan disease indications. For more information,
please visit the company's website at www.xeneticbio.com.
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate" and "intend," among others.
These forward-looking statements are based on Xenetic's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. Factors that could cause actual results to differ
materially include, but are not limited to, uncertainties associated with
completing preclinical and clinical trials for our technologies; the early
stage of product development; the significant costs to develop our products as
all of our products are currently in development, preclinical studies or
clinical trials; obtaining additional financing to support our operations and
the development of our products; obtaining regulatory approval for our
technologies; anticipated timing of regulatory filings and the potential
success in gaining regulatory approval and complying with governmental
regulations applicable to our business. Xenetic does not undertake an
obligation to update or revise any forward-looking statement. The information
set forth herein speaks only as of the date hereof.
CONTACT: Xenetic Biosciences Inc
M. Scott Maguire, Chief Executive Officer
+44 (0)20 3021 1500
Stern Investor Relations
212 362 1200
+44 (0)20 7933 8780
Press spacebar to pause and continue. Press esc to stop.